Nasal Glucagon + Oxymetazoline
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Common Cold
Conditions
Common Cold
Trial Timeline
Mar 1, 2013 → Apr 1, 2013
NCT ID
NCT02778100About Nasal Glucagon + Oxymetazoline
Nasal Glucagon + Oxymetazoline is a phase 1 stage product being developed by Eli Lilly for Common Cold. The current trial status is completed. This product is registered under clinical trial identifier NCT02778100. Target conditions include Common Cold.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02778100 | Phase 1 | Completed |
Competing Products
20 competing products in Common Cold